<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="147918">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01817387</url>
  </required_header>
  <id_info>
    <org_study_id>NIMHK23SCH</org_study_id>
    <nct_id>NCT01817387</nct_id>
  </id_info>
  <brief_title>Enhancing Motivation in Recent Onset Schizophrenia</brief_title>
  <acronym>PRIME</acronym>
  <official_title>Developing an Intervention Strategy to Enhance Motivation in Recent Onset Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project will result in the development of a personalized intervention strategy to
      improve motivation for treatment engagement and functional outcomes in individuals with a
      recent onset of schizophrenia. Motivational impairment is arguably the single most important
      factor that determines a patient's ability to engage in and adhere to effective treatment.
      In phase 1 of our study, ten participants will be enrolled in pilot randomized controlled
      trial comparing the feasibility and tolerability of the two intervention conditions (PRIME
      with computer games vs PRIME + cognitive training). Participants will use the intervention
      over a 2 month period. Participants will undergo pre/post testing and a 6 month follow-up,
      to determine feasibility and efficacy of the interventions. By enhancing motivation,
      schizophrenia patients would be able to engage more fully with treatment and develop full
      and productive lives. This study may also pave the way forward for other health conditions
      in which motivational impairments impede health outcomes.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2014</start_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Psychosocial functioning</measure>
    <time_frame>past 30 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Work status, work performance, social status, social performance, health status, health performance</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>PRIME + CT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 months use of PRIME mobile application on mobile device and 30 hours of cognitive training</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PRIME + CG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 months use of PRIME mobile application on mobile device and 30 hours of computer games</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>PRIME</intervention_name>
    <description>Mobile application designed to improve psychosocial functioning and motivational deficits</description>
    <arm_group_label>PRIME + CT</arm_group_label>
    <arm_group_label>PRIME + CG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cognitive Training</intervention_name>
    <description>Auditory processing training</description>
    <arm_group_label>PRIME + CT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of schizophrenia, schizoaffective, or schizophreniform disorder.

          -  Onset of diagnosis within 5 years.

          -  16-30 years old.

          -  Clinically stable (outpatient status for 1 month and stable dose of medication for 1
             month).

          -  Good general health

        Exclusion Criteria:

          -  Substance dependence within the past 12 months,

          -  Current substance abuse,

          -  No history of neurological disorder
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Danielle A Schlosser, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Danielle A Schlosser, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 25, 2013</lastchanged_date>
  <firstreceived_date>March 13, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
